97 related articles for article (PubMed ID: 17092665)
21. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
Lerman J; Siseles N
Medicina (B Aires); 2008; 68(3):251-7. PubMed ID: 18689159
[TBL] [Abstract][Full Text] [Related]
22. Trials for menopausal women.
Rossouw JE
J Br Menopause Soc; 2004 Dec; 10 Suppl 2():6. PubMed ID: 15667724
[No Abstract] [Full Text] [Related]
23. [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].
Hosoi T
Clin Calcium; 2007 Sep; 17(9):1419-23. PubMed ID: 17767033
[TBL] [Abstract][Full Text] [Related]
24. Choosing the patient for treatment.
Lindsay R
J Endocrinol Invest; 1999 Sep; 22(8):653-5. PubMed ID: 10532254
[No Abstract] [Full Text] [Related]
25. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.
Pelayo I; Haya J; De la Cruz JJ; Seco C; Bugella JI; Diaz JL; Bajo JM; Repolles M
Menopause; 2008; 15(6):1132-8. PubMed ID: 18791486
[TBL] [Abstract][Full Text] [Related]
26. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
Meadows ES; Stock J; Johnston JA
Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
[No Abstract] [Full Text] [Related]
27. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
[TBL] [Abstract][Full Text] [Related]
28. [Hormone replacement Up-to-date. Effect of estrogen therapy (EP) and estrogen-progestogen therapy (EPT) on the bone metabolism].
Taniguchi R; Higuchi T; Mizunuma H
Clin Calcium; 2007 Sep; 17(9):1342-8. PubMed ID: 17767022
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene, tamoxifen and vascular tone.
Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y
Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563
[TBL] [Abstract][Full Text] [Related]
30. Cognitive change, menopause, PMDD and bio-identical hormones.
Studd J
Menopause Int; 2009 Sep; 15(3):93. PubMed ID: 19723674
[No Abstract] [Full Text] [Related]
31. [New forms of estrogenotherapy in postmenopausal osteoporosis].
Meczekalski B; Czyzyk A
Pol Merkur Lekarski; 2009 Jul; 27(157):77-80. PubMed ID: 19650437
[TBL] [Abstract][Full Text] [Related]
32. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
Ohta H
Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
[TBL] [Abstract][Full Text] [Related]
33. Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors".
Choi BG; Vilahur G; Badimon JJ
Circulation; 2009 Oct; 120(17):e147; author reply e148. PubMed ID: 19858421
[No Abstract] [Full Text] [Related]
34. The rise of raloxifene and the fall of invasive breast cancer.
Jordan VC
J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
[No Abstract] [Full Text] [Related]
35. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
[TBL] [Abstract][Full Text] [Related]
36. Individualized therapy for osteoporosis prevention and treatment in women under 60.
de Villiers TJ
Climacteric; 2009 Jun; 12(3):210-2. PubMed ID: 19437197
[No Abstract] [Full Text] [Related]
37. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
[TBL] [Abstract][Full Text] [Related]
39. Cognition and cognitive aging.
Henderson VW
Climacteric; 2007 Oct; 10 Suppl 2():88-91. PubMed ID: 17882681
[TBL] [Abstract][Full Text] [Related]
40. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause.
Birkhäuser MH; Panay N; Archer DF; Barlow D; Burger H; Gambacciani M; Goldstein S; Pinkerton JA; Sturdee DW
Climacteric; 2008 Apr; 11(2):108-23. PubMed ID: 18365854
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
